KOSPIApparel & Living009770

Sam Jung Pulp

₩25,150▼ 1.37%2026-11-18 close
Market Cap
₩62.9B
Turnover
₩5,601,650
Volume
224 shares
Shares out.
2.5M
PER
—
PBR
0.2×
EPS
-₩5,780
Dividend Yield
3.92%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩1,000 per share · Prices as of the 2026-11-18 close

01

Report overview

Shrinking Sales and Continued Operating Losses Amid Production Restructuring

SAM Jung Pulp's base-paper-centered business is under pressure from low-priced imports and oversupply, which turned it to an operating loss in 2025. Operating losses have continued for five straight quarters, and the company is responding by halting the Cheonan base-paper line and shifting toward overseas sourcing and the Haman plant.

  1. 1

    Sales peaked at KRW 178.3 billion in 2023 and have fallen for two consecutive years since, to KRW 148.6 billion in 2025.

  2. 2

    Operating profit fell from KRW 4.87 billion in 2024 to an operating loss of KRW 1.44 billion in 2025, and the company has posted losses for five consecutive quarters from the third quarter of 2025 through the third quarter of 2026.

  3. 3

    Third-quarter 2026 sales were KRW 23.9 billion, down 38.2% from a year earlier, with an operating loss of KRW 1.03 billion.

  4. 4

    Cumulative controlling-shareholder net loss over the last four quarters was KRW 14.4 billion, while the debt ratio at end-2025 was 12.3%, with total liabilities of KRW 35.2 billion against total equity of KRW 287 billion.

  5. 5

    The Cheonan base-paper line stopped operating on September 30, 2026, and headcount has fallen sharply over the past year.

02

Business structure

SAM Jung Pulp is a hygiene paper maker founded in 1974 and listed on KOSPI in 2006. Its business spans tissue base paper, finished products such as rolls and tissue, and merchandise including kitchen towels.

Based on second-quarter 2026 sales, tissue (base paper, rolls and tissue) accounted for 52%, jumbo rolls and kitchen towels and other items for 47%, and rental income for 1%, according to Butler's data compilation.

Based on press reporting from The Tracker, base paper made up 58% of sales and finished products 30% in January to September 2025. Finished products have been produced only at the Pyeongtaek plant, while base paper has been made at Pyeongtaek, Cheonan and Haman.

The Pyeongtaek plant halted production at the end of 2025, and the Cheonan plant stopped its base-paper line on September 30, 2026. The company's disclosure put the halted amount for Cheonan's base-paper segment at KRW 36.8 billion, or 24.75% of sales.

The company cited the domestic inflow of imported base paper, which eroded price competitiveness, and deepening oversupply as reasons for the shutdown. The company is described as a top-five player by sales in the domestic tissue market, behind leaders that are seen as ahead in premium products and technology.

Industry analysis suggests its concentration in mid-to-low-priced tissue leaves it exposed to ultra-low-priced products from China and India.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩38.6B-₩200M−0.5%
2025Q4₩31.3B-₩2.7B−8.5%
2026Q1₩26.9B-₩1.1B−3.9%
2026Q2₩29.6B-₩10,366,921−0.0%
2026Q3₩23.9B-₩1B−4.3%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩174.5B₩4.7B-₩1B2.7%−0.4%9.2%
2023₩178.3B₩7.4B₩14B4.1%6.2%8.3%
2024₩163.9B₩4.9B₩38B3.0%14.7%15.5%
2025₩148.6B-₩1.4B₩31.4B−1.0%10.9%12.3%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-13

04

Earnings analysis

Annual sales rose from KRW 174.5 billion in 2022 to KRW 178.3 billion in 2023, a 2.2% increase, before falling 8.1% to KRW 163.9 billion in 2024 and 9.3% to KRW 148.6 billion in 2025, a two-year decline. Among 2022 to 2025, 2023 was the largest year and 2025 the smallest.

Operating profit rose from KRW 4.67 billion in 2022 to KRW 7.38 billion in 2023, a 58.1% increase, then fell 34.0% to KRW 4.87 billion in 2024 before turning to an operating loss of KRW 1.44 billion in 2025. The operating margin was 2.7% in 2022, 4.1% in 2023, 3.0% in 2024 and -1.0% in 2025.

Net income attributable to controlling shareholders moved from a KRW 957 million loss in 2022 to KRW 14 billion profit in 2023, then KRW 38 billion in 2024 (up 171.6%) and KRW 31.4 billion in 2025 (down 17.3%).

Net income far above operating profit suggests non-operating items played a large role, and their composition should be checked in the regular report notes. Operating cash flow went from KRW 2.22 billion in 2022 to KRW 13.1 billion in 2023 and KRW 21.3 billion in 2024, then fell to KRW 5.81 billion in 2025.

At end-2025, total equity was KRW 287 billion, all attributable to controlling shareholders, total liabilities were KRW 35.2 billion, and the debt ratio fell from 15.5% in 2024 to 12.3%. Quarterly, sales were KRW 38.6 billion in the third quarter of 2025 with an operating loss of KRW 192 million.

In the fourth quarter sales fell 18.8% to KRW 31.3 billion and the operating loss widened to KRW 2.67 billion.

In the first quarter of 2026 sales were KRW 26.9 billion with an operating loss of KRW 1.06 billion, and in the second quarter sales rose 10.0% to KRW 29.6 billion with the operating loss narrowing to KRW 10.37 million.

In the third quarter sales fell 19.5% to KRW 23.9 billion, down 38.2% from a year earlier, and the operating loss widened again to KRW 1.03 billion.

Controlling-shareholder net income was positive in the third quarter of 2025 and the second quarter of 2026 despite operating losses, and the cumulative controlling-shareholder net loss over the last four quarters was KRW 14.4 billion.

05

Industry analysis

Price competition is the core issue in this industry. In its disclosure on the Cheonan halt, the company cited the domestic inflow of imported base paper, which eroded its price competitiveness, and deepening oversupply.

Newspim reported that ultra-low-priced tissue from China and India has flooded the domestic market, weakening the price advantage SAM Jung Pulp had relied on.

In the same report, an industry source pointed to a large technology gap, as leading players defend the market with patented premium technology that improves absorbency and thickness.

SAM Jung Pulp is ranked around fifth by sales in the domestic tissue market, and observers say it has been slow to expand premium product lines.

The company stated in its disclosure that it judged a medium-to-long-term recovery in market conditions to be difficult, and that continued operation would expand operating losses. Its response is to keep selling Cheonan-made products through overseas sourcing and concentrate base-paper output at the Haman plant.

Press reporting put the average utilization of the Pyeongtaek base-paper line at 83.10% in January to September 2025, while the finished-product line ran at 36.29%. That mix points to idle finished-product capacity alongside base-paper oversupply across the industry.

Because a large share of its sales sits in mid-to-low-priced tissue, the company is exposed to swings in price-driven competition.

06

Outlook

In its September 2026 disclosure, the company said it would keep selling Cheonan-made products through overseas sourcing and concentrate base-paper production at the Haman plant after halting the Cheonan base-paper line.

The disclosure states that the company expects profitability and its financial structure to improve through the overseas sourcing shift and stronger production capacity at Haman.

Newspim reported that the Cheonan site is being used as a logistics center, with personnel dispatched one to two times a week to inspect facilities under a minimal management setup. The same report said 60 to 65 Cheonan workers all left through voluntary retirement.

Headcount fell from 299 in the first half of 2025 to 183 in the first half of 2026, a decline of about 39% over the year.

Personnel adjustments also took place when the Pyeongtaek plant stopped at the end of 2025, and an industry source said the loss of production infrastructure and specialist staff makes a shrinking business scale hard to avoid.

A disclosure dated February 2, 2026 reported a change of 30% or more in sales or profit structure. The next checkpoint is how the overseas-sourcing sales model shows up in 2027 sales, which can be confirmed in the 2026 annual report and the first-quarter 2027 quarterly report.

07

Valuation

PER
—
PBR
0.2×
ROE
-5.2%
EPS
-₩5,780
BPS
₩106,666
Dividend per share
₩1,000

Because controlling-shareholder net losses have continued over the last four quarters, the PER cannot be calculated. The price-to-book ratio sits well below 1x, meaning the share price is low relative to book net assets.

Total equity of KRW 287 billion is entirely attributable to controlling shareholders and the debt ratio is 12.3%, so the balance-sheet burden is relatively small. Whether a low price-to-book ratio converts into earnings recovery depends on the operating trend.

Controlling-shareholder net income was KRW 14 billion in 2023 and KRW 38 billion in 2024, while the last four quarters total a net loss of KRW 14.4 billion. The annual general meeting on March 31, 2026 approved a cash dividend with a total payout in the low KRW 2.5 billion range.

Quarterly profit has swung sharply, with net income positive in some quarters even while operating losses persisted.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-13

08

Bull factors

A balance sheet with ample capacity

Total equity at end-2025 was KRW 287 billion against total liabilities of KRW 35.2 billion, and the debt ratio eased from 15.5% in 2024 to 12.3%. Operating cash flow rose from KRW 2.22 billion in 2022 to KRW 21.3 billion in 2024 and remained positive at KRW 5.81 billion in 2025. The modest debt load provides a buffer during the restructuring period.

Room for cost-structure adjustment

In its disclosure, the company expects profitability to improve after halting the Cheonan base-paper line by concentrating overseas sourcing and production at Haman.

The operating loss narrowed to KRW 10.37 million in the second quarter of 2026 from KRW 1.06 billion in the first quarter, and sales rose 10.0% from the prior quarter. The quarterly data show a period in which losses narrowed.

A track record of past profits

Controlling-shareholder net income turned to a KRW 14 billion profit in 2023, then recorded KRW 38 billion in 2024 and KRW 31.4 billion in 2025. Net income well above operating profit in some years means the nature of non-operating items should be checked in the regular reports. The past profit record serves as a reference point for earnings capacity if the business recovers.

09

Bear factors

Two consecutive years of falling sales

Sales fell 8.1% to KRW 163.9 billion in 2024 and 9.3% to KRW 148.6 billion in 2025. Third-quarter 2026 sales of KRW 23.9 billion were down 38.2% from a year earlier. Newspim reported that first-half 2026 sales of KRW 56.5 billion were down 28.12% from KRW 78.6 billion a year earlier.

Five consecutive quarters of operating losses

Operating losses have continued for five consecutive quarters from the third quarter of 2025 through the third quarter of 2026. The third-quarter 2026 operating loss of KRW 1.03 billion widened from the KRW 10.37 million loss in the prior quarter. Cumulative controlling-shareholder net loss over the last four quarters was KRW 14.4 billion.

Import pressure and oversupply

The company cited the domestic inflow of imported base paper and deepening oversupply as reasons for halting the Cheonan line. The halted amount for the Cheonan base-paper segment was KRW 36.8 billion, equal to 24.75% of sales.

Industry analysis also points to ultra-low-priced tissue from China and India eroding price competitiveness in the mid-to-low segment.

10

Risk factors

Pricing and supply structure

The company's disclosure judged that price competitiveness is hard to restore while imported base paper and oversupply persist. Price competition from low-priced products from China and India in the mid-to-low segment could slow any sales recovery. Whether this structure changes will show up in base-paper sales trends.

Production and workforce base

The Pyeongtaek plant stopped at the end of 2025 and the Cheonan base-paper line stopped on September 30, 2026. Headcount fell about 39%, from 299 in the first half of 2025 to 183 in the first half of 2026, and 60 to 65 Cheonan workers took voluntary retirement.

As production capacity and specialist staff shrink, greater reliance on overseas sourcing could bring quality and cost-management burdens.

Business concentration and shareholder returns

A business centered on tissue base paper and finished products is sensitive to price changes in a narrow product set. The March 2026 shareholder meeting approved a cash dividend even as the last four quarters total a KRW 14.4 billion controlling-shareholder net loss. Whether the dividend continues will need to be checked at the next annual settlement.

11

What to watch next

  1. By end-March 2027

    Filing of the 2026 annual report. Check full-year 2026 sales and operating results, and how the Cheonan line halt and the shift to overseas sourcing show up in fourth-quarter results.

  2. Around the March 2027 annual general meeting

    Whether a 2026 year-end dividend is approved. The March 31 meeting last year approved a cash dividend, so this shows whether payouts continue through a loss-making stretch.

  3. Mid-May 2027

    First-quarter 2027 quarterly report, due 45 days after quarter-end. Check whether sales held up and the direction of operating results in the first quarter after the overseas sourcing shift.

12

Overall view

SAM Jung Pulp is a hygiene paper maker centered on tissue base paper and finished products, with sales peaking at KRW 178.3 billion in 2023 before falling for two consecutive years.

It turned to an operating loss of KRW 1.44 billion in 2025, and operating losses have continued for five straight quarters from the third quarter of 2025 through the third quarter of 2026.

On the financial side, the debt ratio at end-2025 was 12.3%, and all of the KRW 287 billion in total equity is attributable to controlling shareholders, so the burden is relatively modest.

On the other hand, the cumulative controlling-shareholder net loss over the last four quarters is KRW 14.4 billion, and the price-to-book ratio sits well below 1x. On the business side, imported base paper, oversupply and low-priced products from China and India are pressuring price competitiveness.

The company is responding by halting the Cheonan base-paper line and concentrating on overseas sourcing and the Haman plant, and operating losses narrowed to KRW 10.37 million in the second quarter of 2026.

Strengths such as financial capacity and room for cost adjustment coexist with weaknesses such as falling sales and continued losses. The next checkpoints are full-year operating results in the 2026 annual report and the direction of operating results in the first-quarter 2027 report.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 17 more articles and sources
  1. jobkorea.co.kr
  2. butler.works
  3. thetracker.co.kr
  4. saramin.co.kr
  5. news.nate.com
  6. moneypie.net
  7. itooza.com
  8. newspim.com
  9. businesspost.co.kr
  10. kpinfo.kr
  11. m.news.nate.com
  12. knowingasset.com
  13. awakeplus.co.kr
  14. pflow.keywordegg.com
  15. catch.co.kr
  16. judal.co.kr
  17. kr.investing.com

Report written 2026-11-14 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis